The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.
|Translated title of the contribution||TNF alpha inhibitors for chronic inflammatory disorders: Lights and shadows|
|Number of pages||8|
|Journal||Medico e Bambino|
|Publication status||Published - May 2012|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health